Mylotarg™ (gemtuzumab ozogamicin) – Expanded indication
June 16, 2020 - The FDA approved Pfizer’s Mylotarg (gemtuzumab ozogamicin), for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older.
Download PDF
